These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 27154395)

  • 1. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and immunological evaluation of hepatitis B virus core virus-like particles containing multiple antigenic peptides of respiratory syncytial virus.
    Lei L; Qin H; Luo J; Tan Y; Yang J; Pan Z
    Virus Res; 2021 Jun; 298():198410. PubMed ID: 33819519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.
    Quan FS; Kim Y; Lee S; Yi H; Kang SM; Bozja J; Moore ML; Compans RW
    J Infect Dis; 2011 Oct; 204(7):987-95. PubMed ID: 21881112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.
    Schmidt MR; McGinnes-Cullen LW; Kenward SA; Willems KN; Woodland RT; Morrison TG
    J Virol; 2014 Sep; 88(17):10165-76. PubMed ID: 24965456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
    McGinnes Cullen L; Schmidt MR; Kenward SA; Woodland RT; Morrison TG
    J Virol; 2015 Jul; 89(13):6835-47. PubMed ID: 25903340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
    Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
    Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus.
    Terhüja M; Siddappa M; Lamichhane P; Meshram CD; Snider TA; Ritchey JW; Oomens AGP
    Viruses; 2024 May; 16(6):. PubMed ID: 38932136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice.
    Mandviwala AS; Huckriede ALW; Arankalle VA; Patil HP
    Virology; 2024 Oct; 598():110194. PubMed ID: 39096774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.
    Lee JS; Kwon YM; Hwang HS; Lee YN; Ko EJ; Yoo SE; Kim MC; Kim KH; Cho MK; Lee YT; Lee YR; Quan FS; Kang SM
    Vaccine; 2014 Oct; 32(44):5866-74. PubMed ID: 25173478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein.
    Kim AR; Lee DH; Lee SH; Rubino I; Choi HJ; Quan FS
    PLoS One; 2018; 13(1):e0191277. PubMed ID: 29338045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
    Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
    Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection.
    Zhang Y; Qiao L; Hu X; Zhao K; Zhang Y; Chai F; Pan Z
    Vaccine; 2016 Jan; 34(2):252-260. PubMed ID: 26643933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
    Murawski MR; McGinnes LW; Finberg RW; Kurt-Jones EA; Massare MJ; Smith G; Heaton PM; Fraire AE; Morrison TG
    J Virol; 2010 Jan; 84(2):1110-23. PubMed ID: 19889768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.